Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFN-gamma in Chronic Granulomatous Disease (CGD) Mutations
NCT01147042Phase 4Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2010
- Primary completion
- Nov 2014
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, open-label trial of interferon gamma-1b in chronic granulomatous disease (CGD) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Basal and PMA-stimulated O2 Production Detected by Ferricytochrome c Reduction in Neutrophils at 21 weeks. Started May 2010; status: terminated.
02
Drugs
interferon gamma-1b
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT01147042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01147042.